Fierce Biotech's James Waldron covered the biotech industry with a review to date. He explains that while the biotech bull market hasn’t charged back in 2023 as many had hoped, European-focused venture capital firms don’t seem to have had problems bringing in money. BioGeneration Ventures Managing Partner Oskar Slotboom was interviewed by James for his piece ‘The fundamentals are really strong’: Why investors are staying loyal to European biotech in 2023.
Click here to read the article online.